Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer

References

• Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):105–15. doi:10.1200/JCO.2009.23.7370.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(9):983–991. doi:10.1200/JCO.2014.58.1967.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi:10.1016/S1470-2045(17)30904-X.
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033.
   PubMed Web of Science ®Google Scholar
• Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2016;22(6):1499–1509. doi:10.1158/1078-0432.CCR-15-1125.
   PubMed Web of Science ®Google Scholar
• Azim HA, Vingiani A, Peccatori F, Viale G, Loi S, Pruneri G. Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast Edinb Scotl. 2015;24(3):290–293. doi:10.1016/j.breast.2015.01.009.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L, et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;12(5):864–875. doi:10.1080/15548627.2016.1154244.
   PubMed Web of Science ®Google Scholar
• Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8(9):737–744. doi:10.1038/nri2394.
   PubMed Web of Science ®Google Scholar
• Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114(1):37–43. doi:10.1111/j.1365-2567.2004.02006.x.
   PubMed Web of Science ®Google Scholar
• Lang TJ. Estrogen as an immunomodulator. Clin Immunol. 2004;113(3):224–230. doi:10.1016/j.clim.2004.05.011.
   PubMed Web of Science ®Google Scholar
• Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109(3):573–579. doi:10.1007/s10549-007-9683-8.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat. 2011;126(1):215–220. doi:10.1007/s10549-010-1224-1.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhu S, Li X, Wang F, Hu F, Li D, Zhang W, Li X. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat. 2009;117(1):141–150. doi:10.1007/s10549-008-0228-6.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT, Lash TL. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103(19):1461–1468. doi:10.1093/jnci/djr291.
   PubMed Web of Science ®Google Scholar
• Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control CCC. 2007;18(6):613–620. doi:10.1007/s10552-007-9003-y.
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628–638. doi:10.18632/oncotarget.101009.
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(19):2635–2644. doi:10.1200/JCO.2010.33.5422.
   PubMed Web of Science ®Google Scholar
• Haukka J, Niskanen L, Auvinen A. Risk of cause-specific death in individuals with cancer-modifying role diabetes, statins and metformin. Int J Cancer. Aug 25 2017. doi:10.1002/ijc.31016.
   PubMed Web of Science ®Google Scholar
• Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 2015;112(6):1809. doi:10.1073/pnas.1417636112.
   PubMed Web of Science ®Google Scholar
• Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res. 2017;5(1):9–16. doi:10.1158/2326-6066.CIR-16-0103.
   PubMed Web of Science ®Google Scholar
• Shaashua L, Shabat-Simon M, Haldar R, Matzner P, Zmora O, Shabtai M, Sharon E, Allweis T, Barshack I, Hayman L, et al. Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-ii randomized trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2017 May 10;23:4651–4661. doi:10.1158/1078-0432.CCR-17-0152.
   PubMed Web of Science ®Google Scholar
• Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov. 2015;5(1):35–42. doi:10.1158/2159-8290.CD-14-0621.
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Filipazzi P, Grioni M, Iero M, Milito AD, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating t lymphocytes. Cancer Res. 2012;72(11):2746–2756. doi:10.1158/0008-5472.CAN-11-1272.
   PubMed Web of Science ®Google Scholar
• Bellone M, Calcinotto A, Filipazzi P, De Milito A, Fais S, Rivoltini L. The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. Oncoimmunology. 2013;2(1):e22058. doi:10.4161/onci.22058.
   PubMed Web of Science ®Google Scholar
• Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol. 2013:3. doi:10.3389/fonc.2013.00231.
   PubMedGoogle Scholar
• Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(1):30–38. doi:10.1158/1078-0432.CCR-14-1716.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, Weber JS, Zarour HM, Kefford R, Loboda A, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol. 2015;33(15):3001. doi:10.1200/jco.2015.33.15_suppl.3001.
   Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MCR, Harjunpää H, Ngiow SF, Takeda K, Young A, O’Donnell JS, Allen S, Smyth MJ, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–1399. doi:10.1158/2159-8290.CD-16-0577.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516. doi:10.1038/ncomms3516.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Tryndyak VP, Pogribna M, Shpyleva S, Surratt G, Gamboa Da Costa G, Beland FA. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents. Int J Oncol. 2013;42(5):1822–1832. doi:10.3892/ijo.2013.1855.
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle Georget Tex. 2010;9:3807–3814.
   PubMed Web of Science ®Google Scholar
• Wang B-Y, Zhang J, Wang J-L, Sun S, Wang Z-H, Wang L-P, Zhang Q-L, Lv -F-F, Cao E-Y, Shao Z-M, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res CR. 2015;34:85. doi:10.1186/s13046-015-0194-x.
   PubMed Web of Science ®Google Scholar
• Liu S, Uppal H, Demaria M, Desprez P-Y, Campisi J, Kapahi P. Simvastatin suppresses breast cancer cell proliferation induced by senescent cells. Sci Rep. 2015;(5). doi:10.1038/srep17895.
   Google Scholar
• Alalem M, Ray A, Ray BK. Metformin induces degradation of mTOR protein in breast cancer cells. Cancer Med. 2016;5(11):3194–3204. doi:10.1002/cam4.896.
   PubMed Web of Science ®Google Scholar
• Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H, Masaki T. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKa/mTOR pathway in vitro and in vivo. Oncotarget. 2016;8(5):8536–8549. doi:10.18632/oncotarget.14345.
   Google Scholar
• Polydorou C, Mpekris F, Papageorgis P, Voutouri C, Stylianopoulos T. Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Oncotarget. 2017;8(15):24506–24517. doi:10.18632/oncotarget.15534.
   PubMedGoogle Scholar
• Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, et al. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett. 2017 Aug 30;409:9–19. doi:10.1016/j.canlet.2017.08.028.
   PubMed Web of Science ®Google Scholar
• Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, Kaye SB, Cassidy J. The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol. 1998;10(1):35–38. doi:10.1016/S0936-6555(98)80109-X.
   PubMedGoogle Scholar
• Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol. 2017;83(4):927–930. doi:10.1111/bcp.13155.
   PubMed Web of Science ®Google Scholar
• Rodrigues AC, Curi R, Britto LRG, Rebbechi IMM, Hirata MH, Bertolami MC, Bernik MMS, Dorea EL, Hirata RDC. Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta. 2006;1760(12):1866–1873. doi:10.1016/j.bbagen.2006.08.003.
   PubMed Web of Science ®Google Scholar
• Wang E, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46(1):160–165. doi:10.1128/AAC.46.1.160-165.2002.
   PubMed Web of Science ®Google Scholar
• Vdovin AS, Maximchik PV, Kulikov AV, Zhivotovsky BD, Gogvadze VG. Inhibition of P-glycoprotein stimulates cell death under Hypoxia-mimicking conditions. Dokl Biochem Biophys. 2017;472(1):27–30. doi:10.1134/S1607672917010100.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44–49. doi:10.1111/j.1365-2125.2008.03303.x.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012.
   PubMed Web of Science ®Google Scholar
• Trabert B, Ness RB, Lo-Ciganic W-H, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the ovarian cancer association consortium. J Natl Cancer Inst. 2014;106(2):djt431. doi:10.1093/jnci/djt431.
   PubMedGoogle Scholar
• Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM. Australian national endometrial cancer study group. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013;132(5):1146–1155. doi:10.1002/ijc.27717.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu P, Chen L, Yang S, Shen H-Y, Yu D, Zhang X, Zhong S, Zhao J, Tang J. Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015;36(11):8259–8266. doi:10.1007/s13277-015-4027-5.
   PubMedGoogle Scholar
• Anderson SL, Duke-Novakovski T, Singh B. The immune response to anesthesia: part 2 sedatives, opioids, and injectable anesthetic agents. Vet Anaesth Analg. 2014;41(6):553–566. doi:10.1111/vaa.12191.
   PubMed Web of Science ®Google Scholar
• Cho JS, Lee M-H, Kim SI, Park S, Park HS, Oh E, Lee JH, Koo B-N. The effects of perioperative anesthesia and analgesia on immune function in patients undergoing breast cancer resection: a prospective randomized study. Int J Med Sci. 2017;14(10):970–976. doi:10.7150/ijms.20064.
   PubMed Web of Science ®Google Scholar
• Buckley A, McQuaid S, Johnson P, Buggy DJ. Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study. Br J Anaesth. 2014;113(1):i56–62. doi:10.1093/bja/aeu200.
   PubMedGoogle Scholar
• Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482–491. doi:10.1038/onc.2009.356.
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011;30(10):1147–1158. doi:10.1038/onc.2010.500.
   PubMed Web of Science ®Google Scholar
• Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med. 2012;4(143):143ra99. doi:10.1126/scitranslmed.3003807.
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, Vacchelli E, Galluzzi L, Kroemer G. Fluorescent biosensors for the detection of HMGB1 release. Methods Mol Biol Clifton NJ. 2013;1004:43–56. doi:10.1007/978-1-62703-383-1_4.
   PubMedGoogle Scholar
• Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology. 2013;2(2):e23082. doi:10.4161/onci.23082.
   PubMed Web of Science ®Google Scholar
• Madeo F, Eisenberg T, Pietrocola F, Kroemer G. Spermidine in health and disease. Science. 2018;359:6374. doi:10.1126/science.aan2788.
   Web of Science ®Google Scholar
• Pietrocola F, Bravo-San Pedro JM, Galluzzi L, Kroemer G. Autophagy in natural and therapy-driven anticancer immunosurveillance. Autophagy. 2017;13(12):2163–2170. doi:10.1080/15548627.2017.1310356.
   PubMed Web of Science ®Google Scholar
• Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30(1):147–160. doi:10.1016/j.ccell.2016.05.016.
   PubMed Web of Science ®Google Scholar
• Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78(7):1779–1791. doi:10.1158/0008-5472.CAN-17-2460.
   PubMed Web of Science ®Google Scholar
• Vishvakarma NK, Singh SM. Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole. Biochimie. 2011;93(10):1786–1796. doi:10.1016/j.biochi.2011.06.022.
   PubMed Web of Science ®Google Scholar
• Huang W-S, Tsai C-H, Lin -C-C, Muo C-H, Sung F-C, Chang Y-J, Kao C-H. Relationship between zolpidem use and stroke risk: a Taiwanese population-based case-control study. J Clin Psychiatry. 2013;74(5):e433–438. doi:10.4088/JCP.12m08181.
   PubMed Web of Science ®Google Scholar
• Yang Y-W, Hsieh T-F, Yu C-H, Huang Y-S, Lee -C-C, Tsai T-H. Zolpidem and the risk of Parkinson’s disease: a nationwide population-based study. J Psychiatr Res. 2014;58:84–88. doi:10.1016/j.jpsychires.2014.07.003.
   PubMed Web of Science ®Google Scholar
• Kao C-H, Sun L-M, Liang J-A, Chang S-N, Sung F-C, Muo C-H. Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc. 2012;87(5):430–436. doi:10.1016/j.mayocp.2012.02.012.
   PubMed Web of Science ®Google Scholar
• Ramirez K, Niraula A, Sheridan JF. GABAergic modulation with classical benzodiazepines prevent stress-induced neuro-immune dysregulation and behavioral alterations. Brain Behav Immun. 2016;51:154–168. doi:10.1016/j.bbi.2015.08.011.
   PubMed Web of Science ®Google Scholar
• Ramirez K, Sheridan JF. Antidepressant imipramine diminishes stress-induced inflammation in the periphery and central nervous system and related anxiety- and depressive- like behaviors. Brain Behav Immun. 2016;57:293–303. doi:10.1016/j.bbi.2016.05.008.
   PubMed Web of Science ®Google Scholar
• Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, Drabick JJ, Schell TD. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology. 2018;7(3):e1405205. doi:10.1080/2162402X.2017.1405205.
   PubMed Web of Science ®Google Scholar
• Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23(3):554–562. doi:10.1016/j.cmet.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Renzi C, Kaushal A, Emery J, Hamilton W, Neal RD, Rachet B, Rubin G, Singh H, Walter FM, de, et al. Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. Nat Rev Clin Oncol. 2019 Jul 26. doi:10.1038/s41571-019-0249-6.
   PubMed Web of Science ®Google Scholar
• Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol. Sep 21 2016. doi:10.1200/JCO.2004.00.9753.
   Google Scholar
• Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO) project. Ecancermedicalscience. 2014;8:442. doi:10.3332/ecancer.2014.442.
   PubMedGoogle Scholar
• Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van Den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015;26(2):259–271. doi:10.1093/annonc/mdu450.
   PubMed Web of Science ®Google Scholar
• Pierga J-Y, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu M-C, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat. 2010;122(2):429–437. doi:10.1007/s10549-010-0939-3.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Hamy A-S, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu M-C, Bertheau P, Guinebretière JM, Saghatchian M, et al. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. Eur J Cancer. 2017;75(SupplementC):323–332. doi:10.1016/j.ejca.2017.01.008.
   PubMedGoogle Scholar
• Pierga J. Whole expression genome array can be used in daily practice for selecting neo-adjuvant treatment. Ann Oncol Abstr ESMO. 2012;23(9):Abstract 245O.
   Google Scholar
• de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, et al. Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients. BMC Cancer. 2011;11:215. doi:10.1186/1471-2407-11-215.
   PubMed Web of Science ®Google Scholar
• Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, et al. Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial. Breast Edinb Scotl. 2013;22(6):1052–1059. doi:10.1016/j.breast.2013.08.015.
   PubMed Web of Science ®Google Scholar
• Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, et al. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2016 Sep 3;159:499–511. doi:10.1007/s10549-016-3961-2.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4.
   PubMed Web of Science ®Google Scholar
• Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol Off J US Can Acad Pathol Inc. 2015;28(9):1185–1201. doi:10.1038/modpathol.2015.74.
   PubMed Web of Science ®Google Scholar
• Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde J-G, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(13):3989–3998. doi:10.1158/1078-0432.CCR-07-0078.
   PubMed Web of Science ®Google Scholar
• Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. doi:10.1038/s41598-017-17204-5.
   PubMed Web of Science ®Google Scholar
• R Development Core Team. R: a language and environment for statistical computing. R Found Stat Computing, Vienna, Austria. 2011. http://www.R-project.org.
   Google Scholar